- Every June 29 marks World Scleroderma Day because on this date, but in 1940, the Swiss artist Paul Klee passed away.
- The anniversary seeks to recognize the value of those people who live with the disease.
- It also aims to claim equal treatment and care for patients around the world.
Systemic sclerosis, also known as sclerodermaIt is a rare disease that mainly affects women between 30 and 50 years of age. It is characterized because it causes chronic inflammation, hardening and thickening of the skin due to an abnormal healing process (fibrosis).
It is estimated that 90% of these patients will develop interstitial lung disease (EPI), a condition that generates fibrosis of the airways. For which, it is calculated, up to 35% of patients will die within the first 10 years, this being, therefore, one of the main complications associated with scleroderma.
The fact that originated this date
With the above in mind, every June 29 marks the World Scleroderma Day. The choice of this date is not fortuitous but coincides with the death of Paul Klee, a Swiss artist affected by this disease, who died on June 29, 1940.
Therefore, this event seeks to recognize the value of those people living with scleroderma. In addition, it also aims to claim equal treatment and care for patients around the world.
Scleroderma is an autoimmune disease that involves the buildup of scar-like tissue on the skin.
– Francisco J. Fernández Clamont (@FcoFdzClamont) June 29, 2022
At a press conference held within the framework of the World Systemic Sclerosis Day, Dr. Isabel Balderas, medical manager of the highly specialized area of Boehringer Ingelheim Mexico, Central America and the Caribbean, presented a double campaign. The objective is to create awareness about the most important aspects of this condition, such as the importance of evaluating the impact of the disease. With the hashtags # MásAlládelaPiel and #BuscandoElSol, she refers to the official flower of this disease, the sunflower, and to the constant search of patients for a timely diagnosis.
“Being a leader in the development of treatments for conditions with a strong unmet medical need such as scleroderma and interstitial lung disease also commits us to strengthening the knowledge that patients, caregivers and first contact physicians may have of these diseases.”
In her participation, Dr. Mayra Mejía, a specialist in pulmonology, explained the impact of PID in patients with systemic sclerosis.
“Airway fibrosis due to interstitial lung disease will begin in the first three years after the onset of symptoms, which is why it is important that patients access treatment at this early stage when we can delay the progression of this disabling and fatal disease. ”.
For her part, Dr. Natllely Ruiz Gómez, a specialist in rheumatology, explained the skin, gastrointestinal, cardiac, renal and joint manifestations of this condition.
At first, the appearance of symptoms such as joint pain, numbness and discoloration in the fingers and toes stands out. Also painful ulcers and swelling in the fingers added to the tightness of the skin. Therefore, the main indication if any of the manifestations is present is to see a rheumatologist immediately to receive an assessment and make a correlation with possible pulmonary involvement.
Tina Ampudia Mello, founding president of the Mexican Association for Orientation, Support and Fight Against Scleroderma AC He presented his experience as a scleroderma patient and the actions that drive him as a group:
“From the patient groups we continue to push efforts to make visible that the impact of scleroderma transcends the medical plane and has an emotional and economic impact. Being a woman in Mexico is already a challenge in itself, which added to suffering from a highly disabling disease in the stage of greatest productivity of life can be disastrous, that is why our commitment to increase knowledge about this condition.”